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ABSTRACT  During organ development and remodeling, macrophages support angiogenesis, not only 
by secreting proangiogenic growth factors and matrix-remodeling proteases, but also by physically 
interacting with the sprouting vasculature to assist the formation of complex vascular networks. 
Recent data further indicate that embryonic and tumor-associated macrophages express similar 
genetic programs, possibly suggesting convergent functions in organogenesis and tumorigenesis. 
In this article, we review the role of macrophages in development, tissue injury and regeneration, 
by focusing on the mechanisms used by subsets of these cells, such as the TIE2-expressing ma-
crophages,  to regulate angiogenesis and lymphangiogenesis in both fetal and post-natal life.
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The monocyte/macrophage system
In adulthood, monocytes are short-lived cells that derive from 
bone marrow (BM) hematopoietic stem cells (HSCs) and circulate 
in the peripheral blood. In humans, monocytes represent 5-8% of 
all circulating leukocytes. Under inflammatory conditions, mono-
cytes extravasate and migrate into tissues, where they differentiate 
into macrophages and dendritic cells (DCs). It is now clear that 
circulating monocytes are a heterogeneous cell population, which 
may comprise distinct subsets with distinguishing phenotypic and 
functional features (Geissmann et al., 2010). Circulating monocytes 
can be conveniently identified by their physical properties (light 
scattering) and expression of colony-stimulating factor-1 receptor 
(CSF-1R, or CD115). Based on their phenotype (surface marker 
profile and gene expression) and functions, both mouse and human 
monocytes can be divided into at least two main subsets, which 
have been termed “inflammatory” or “classical” monocytes (Gr1+/
Ly-6Chigh in the mouse; CD14+CD16– in the human), and “resident”, 
“patrolling” or “non-classical” monocytes (Gr1–/Ly6Clow/– in the 
mouse; CD14low/–CD16+ in the human), respectively (Geissmann 
et al., 2010; Ziegler-Heitbrock et al., 2010). A third subset has 
been described that displays intermediate features between the 
two main subsets (Geissmann et al., 2010; Ziegler-Heitbrock et 
al., 2010). Whereas “inflammatory” monocytes participate in in-
flammatory responses induced by pathogens or tissue damage, 
and can rapidly differentiate into inflammatory macrophages or 
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DCs upon their extravasation, the role of “resident” monocytes 
is still poorly understood. Recent studies have suggested that 
“resident” monocytes patrol blood vessels (hence “patrolling” 
monocytes) and extravasate in response to vascular damage to 
facilitate tissue healing and revascularization (Auffray et al., 2007; 
Nahrendorf et al., 2007). 
Both in development and adulthood, tissue macrophages 
phagocytose pathogens, dead cells, cellular debris, and various 
components of the extra-cellular matrix (ECM). Ilya Ilyich Mechnikov 
was the first to describe the process of phagocytosis in 1882, and 
macrophages were named after this feature as “big eaters” (from 
ancient Greek, makros “large” + phagein “eat”). However, it is now 
clear that macrophages are not only big eaters of pathogens and 
dead cells, but also important components of the stromal archi-
tecture of several tissues and organs, where they regulate organ 
homeostasis and remodeling (Pollard, 2009). For instance, Kupffer 
cells are specialized macrophages that line hepatic capillaries 
(termed sinusoids) in the liver, where they scavenge senescent 
erythrocytes, a process referred to as hemocatheresis. During 
development and tissue healing or regeneration, macrophages 
496    S. Nucera et al.
stimulate angiogenesis and facilitate tissue remodeling by secre-
ting a number of proteases and growth factors (Pollard, 2009). In 
many tissues, macrophages can be identified by their expression 
of a few distinguishing markers, such as F4/80 (in the mouse) and 
CD68, an endosomal glycoprotein also known as macrosialin (both 
in mouse and human).
The ontogeny of macrophages
The first macrophages appear very early during mouse devel-
opment, precisely at 7.5 days post-coitum (dpc). Bertrand and 
co-workers proposed a three-wave model for macrophage ontog-
eny, which takes place in the extra-embryonic yolk sac before the 
onset of definitive hematopoiesis (Bertrand et al., 2005). The first 
macrophages that are found in the yolk sac have been reported 
to be of maternal origin; these maternally-derived macrophages 
might constitute a transient population and rapidly decrease at 8.5-9 
dpc. The second and third macrophage populations appear in the 
yolk sac between 8 and 9 dpc and are derived from monopotent 
and erythromyeloid macrophage precursor cells, respectively 
(Bertrand et al., 2005). Starting from 8.5 dpc, macrophages can be 
readily identified in both extra-embryonic and embryonic tissues, 
including yolk sac, neural, inter-somitic and inter-digital tissues 
(Pucci et al., 2009). Definitive hematopoiesis (i.e., the generation 
of hematopoietic cells from multipotent HSCs) starts at 9.5-10 dpc 
in the Aorto-Gonado-Mesonephron (AGM) region of the embryo 
to continue in the fetal liver, spleen and BM at later stages of de-
velopment. From the onset of definitive hematopoiesis throughout 
adult life, macrophages are thought to originate from HSCs through 
circulating monocyte intermediates. However, the precise origin 
of tissue-resident (e.g., the long-lived liver Kupffer cells and brain 
microglia) as well as inflammatory macrophages (i.e., macrophages 
that acutely infiltrate inflamed tissues) is still a matter of debate 
(Geissmann et al., 2003; Geissmann et al., 2010). For instance, 
it is not clear whether Kupffer cells and microglia originate from 
adult HSC-derived monocytes or self-renewing, nonHSC-derived 
macrophage precursors of yolk-sac origin (Chan et al., 2007; 
Geissmann et al., 2010). A recent study showed that postnatal 
HSCs do not significantly contribute to microglia homeostasis in 
the adult mouse brain (Ginhoux et al., 2010). In vivo lineage trac-
ing studies indeed showed that brain microglial cells derive from 
primitive myeloid progenitors that arise before 8 dpc (Ginhoux et 
al., 2010). There is also evidence that, during inflammation, tissue 
macrophages undergo rapid in situ proliferation in order to increase 
population density (Jenkins et al., 2011). These recent studies 
therefore indicate that resident macrophages can self-renew and 
expand in situ under the influence of appropriate stimuli and/or 
at selected anatomical sites (Ginhoux et al., 2010; Jenkins et al., 
2011). Nevertheless, it is also clear that total body irradiation can 
enhance tissue-resident macrophage turnover from BM-derived, 
circulating monocytes (Biffi et al., 2004; De Palma et al., 2003). 
The role of macrophages in development
Several transcription factors have been implicated in monocyte/
macrophage development and commitment. PU.1 regulates both 
embryonic and adult hematopoiesis by interacting with many other 
transcription factors, including GATA1. PU.1–/– mice die at a late 
embryonic stage or shortly after birth and have impaired myelo- 
and lymphopoiesis (Iwasaki and Akashi, 2007). The conditional 
deletion of PU.1 in the adult BM results in a complete loss of 
common myeloid (CMP) and lymphoid (CLP) progenitors, but not 
megakaryocyte-erythroid progenitors (MegE), indicating that PU.1 
is necessary for multipotent progenitors to proceed to the CMP/
CLP but not MegE stage (Iwasaki and Akashi, 2007). Among the 
differentiated hematopoietic cells, PU.1 is expressed in the myeloid 
but not lymphoid, megakaryocyte and erythroid lineages, indicating 
a role for PU.1 in myeloid cell commitment and differentiation. PU.1 
modulates the expression of several myeloid-specific genes, includ-
ing granulocyte-colony stimulating factor (G-CSF) and granulocyte/
monocyte-colony stimulating factor (GM-CSF) receptors (Burda et 
al., 2010). Because PU.1–/– mice display only minor erythropoietic 
and megakariocytopoietic defects and remain vital until perinatal 
developmental stages, they represent a widely used model to study 
the effects of macrophage deficiency on organogenesis. 
PU.1-deficient mice display an osteopetrotic phenotype (Tondravi 
et al., 1997). Osteopetrosis is a metabolic bone disease charac-
terized by the lack of BM cavities and defects in bone resorption. 
These defects are due to the lack of osteoclasts, a form of highly 
specialized macrophage that resides in the bone and regulates 
its remodeling. Similar to PU.1–/– mice, Csf-1op/op mice (which lack 
CSF-1, a key growth factor responsible for the proliferation, differ-
entiation, survival, and chemotaxis of monocytes/macrophages and 
their precursors) and Csf-1r–/– mice also display an osteopetrotic 
phenotype. Interestingly, both Csf-1op/op and Csf-1r–/– mutant mice 
are severely depleted of most, but not all macrophage populations 
(Pollard, 2009). Although Csf-1op/op mice have many developmen-
tal abnormalities that can be attributed to the lack of individual 
macrophage populations (Pollard, 2009), they are viable and can 
be used as a model of adult macrophage deficiency in several 
experimental settings, including tumor progression (Lin et al., 
2001). The phenotype of Csf-1r–/– mice is similar to that of Csf-1op/
op mice, but the former are more severely affected and rarely live 
beyond a few weeks of age.
Csf-1op/op mice have reduced numbers of macrophages in their 
tissues, particularly in the kidney, mammary and pancreatic glands. 
In the developing mammary gland, CSF-1 secreted by epithelial 
cells recruits CSF-R1+ (CD115+) macrophages to the terminal end 
buds (Pollard, 2009). At this anatomical site, macrophages pro-
duce many growth factors and proteases that facilitate epithelial 
cell growth and invasion of the surrounding connective tissue; in 
fact, Csf-1op/op mice show reduced complexity of mammary ductal 
branching due to impaired recruitment of infiltrating macrophages 
at the terminal end buds (Pollard, 2009). 
Rae and co-workers studied embryonic macrophages in Csf-
1r-GFP transgenic mice, which express GFP preferentially in 
myelomonocytic cells (Rae et al., 2007). Csf-1r-GFP–positive 
macrophages represented 3-10% of all embryo-derived cells at 
11.5 dpc and were particularly abundant in developing limbs, lens, 
thymus and olfactory bulb. The authors then isolated GFP-positive 
macrophages from the brain, lung and kidney of 12 dpc embryos 
and compared their gene expression with that of macrophages 
isolated from adult organs. Microarray analyses indicated that 
embryonic macrophages, as compared to their adult macrophage 
counterpart, were enriched in transcripts associated with “wound-
healing” and “angiogenesis” signatures. Among the up-regulated 
genes were mannose receptor (Mrc1), the scavenger receptors 
Msr1 and Mrs2, the chemokine Ccl24, and the complement protein 
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C1q (Rae et al., 2007). These genes are involved in recognition 
and engulfment of dying cells and components of the ECM, and 
are also up-regulated in tumor-associated macrophages (TAMs), 
as discussed below. 
In the kidney, organogenesis involves the infiltration of the 
metanephric mesenchyme by the ureteric bud and subsequent 
branching morphogenesis. Rae and co-workers also reported 
that macrophages associate with developing renal tubules and 
blood vessels, perhaps facilitating their invasion and expansion 
into the surrounding connective tissue (Rae et al., 2007). The 
authors further showed that embryonic macrophages promote 
tissue growth in metanephric explant cultures of 11.5 dpc embryos, 
partially in a CSF-1–dependent manner (Rae et al., 2007). These 
data corroborate the notion that macrophages orchestrate tissue 
and organ morphogenesis by producing chemokines that in turn 
attract and/or activate other cell types (e.g., fibroblasts) in the tissue 
microenvironment. Thus, the CSF-1 / CSF-1R axis – via its effects 
on myelo-monocytopoiesis – represents a molecular hub that is 
important for physiologic tissue growth and remodeling, both in 
development and adulthood.
Macrophage regulation of angiogenesis in development 
and post-natal tissue remodeling
The formation of new, functional blood vessels requires the 
sprouting of pre-existing blood vessels and their subsequent fusion 
with other blood vessels, a process known as vascular anastomosis 
(Ribatti, 2010; Eichmann et al., 2004; Carmeliet, 2005). Little is 
known about the mechanisms by which the endothelial cells (ECs) 
present at the leading edge of vascular sprouts (named endothelial 
“tip” cells) integrate directional cues from the environment and fuse 
to form new functional blood vessels. Fantin and co-workers have 
recently shown that yolk sac-derived macrophages mediate the 
fusion of endothelial tip cells and increase vascular complexity in 
the developing hindbrain (Fantin et al., 2010). 
In wild-type embryos, yolk sac-derived macrophages were 
often observed in close association with sprouting blood vessels 
(Fantin et al., 2010). In the subventricular zone of the hindbrain, 
macrophages accumulated between 10-11.5 dpc, a time point dur-
ing which blood vessels branch to form the subventricular vascular 
plexus. Once the subventricular vascular plexus had formed, mac-
rophages decreased in this area while accumulated in deeper brain 
layers, concomitantly to the branching of radial arteries (Fantin et 
al., 2010). These data suggest that macrophages associate with 
sites of active vascular branching in the developing hindbrain. To 
further study the role of macrophages in vascular patterning, the 
authors used macrophage-deficient PU.1–/– embryos (Fantin et al., 
2010). They found that the hindbrain of PU.1 mutants displayed 
normal numbers of vascular sprouts but fewer intersections among 
the blood vessels, indicating reduced vascular network complex-
ity. Of note, the vascular phenotype of PU.1–/– embryos was less 
severe than that of Vegfa120/120 mutants, which have impaired 
angiogenesis due to the absence of the master proangiogenic 
factor, vascular endothelial growth factor (VEGF)-A. Together, 
these findings suggest that macrophages support blood vessel 
formation downstream to VEGF-induced angiogenesis (Fantin 
et al., 2010). The authors further showed that yolk sac-derived 
but not circulating monocyte-derived macrophages are important 
for brain angiogenesis in the developing brain. This may indicate 
that yolk sac macrophages infiltrate the brain before a functional 
circulation is established (Fantin et al., 2010), in agreement with 
other studies (Ginhoux et al., 2010). 
From a mechanistic standpoint, the study of Fantin and co-wor-
kers suggested that macrophages promote vascular anastomosis 
in the developing hindbrain by physically assisting endothelial tip 
cell fusion through direct cell-to-cell contacts (Fantin et al., 2010). A 
similar mechanism has been described recently by Rymo and co-
workers, who showed that macrophages/microglial cells associate 
with endothelial tip cells also in the developing retina (Rymo et al., 
2011). Retinal macrophages were frequently found at sites where 
endothelial tip cells contact each other through their filopodia, and 
were present at 1:2 numeric ratio with the endothelial tip cells. 
These observations suggest that each macrophage/microglial cell 
can theoretically contact two neighboring endothelial tip cells. Inter-
estingly, genetic ablation of microglia in Csf-1op/op mice determined 
a sparser vascular network associated with reduced numbers of 
filopodia-bearing sprouts. Moreover, the retinal vascular sprouts of 
macrophage-deficient mice were fewer and mostly radially-oriented, 
whereas those of wild-type mice displayed much higher complexity 
and were both radially- and forward-oriented, thus forming more 
intersections (Rymo et al., 2011). The authors then asked whether 
microglial cells stimulate vessel branching through direct contacts 
with the endothelial network. To address this question, they used 
mouse aortic rings cultured with or without embedded microglia, 
and found that microglia induced significant vascular sprouting 
long before the cells had made physical contact with the growing 
vessel network (Rymo et al., 2011). These data indicate that direct 
macrophage/EC cell-to-cell contacts are not strictly essential for 
vascular sprouting in the mouse aortic ring assay. Nevertheless, 
it cannot be excluded that cell-to-cell contacts are essential for 
directional, vascular morphogenesis in vivo, as implied by imaging 
data (Fantin et al., 2010; Rymo et al., 2011).
The requirement of macrophage/EC cell-to-cell contacts for 
vascular network formation is also suggested by studies showing 
that certain TAMs, namely the TIE2-expressing macrophages 
(TEMs), physically interact with tumor blood vessels and promote 
angiogenesis in mouse tumor models (De Palma et al., 2003; De 
Palma et al., 2005; De Palma et al., 2008; De Palma and Naldini, 
2009; Pucci et al., 2009; Mazzieri et al., 2011; Welford et al., 2011; 
Squadrito and De Palma, 2011). Interestingly, both TEMs and em-
bryonic macrophages that assist vascular morphogenesis express 
the angiopoietin receptor, TIE2 (De Palma et al., 2005; Pucci et 
al., 2009; Mazzieri et al., 2011; Fantin et al., 2010; Gordon et al., 
2010). TIE2 is a tyrosine kinase receptor broadly expressed by 
ECs; it regulates angiogenesis and vascular morphogenesis both in 
development and adulthood (Augustin et al., 2009). Activated ECs 
(such as those of angiogenic blood vessels) secrete high levels 
of the TIE2 ligand, angiopoietin-2 (ANG2), which binds TIE2 both 
autocrinally on ECs and paracrinally on perivascular monocytes/
macrophages to induce them to become highly proangiogenic 
(Coffelt et al., 2010b). Such reciprocal signaling might regulate 
macrophage/EC interactions and facilitate macrophage-assisted 
vascular patterning both in developing organs and, as recently 
shown, in mouse tumor models (Mazzieri et al., 2011).
Macrophages have also been implicated in the post-natal remod-
eling of the retinal vasculature. Retinal development requires the 
formation of a temporary vascular plexus (the hyaloid vessels), which 
is subsequently remodeled through a vascular regression phase. 
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Following remodeling, the dense primary vasculature is replaced 
by a narrower, smaller caliber secondary vasculature (Ishida et al., 
2003; Lobov et al., 2005). In the mouse, retinal vascular regression 
occurs after birth and involves the activity of macrophages. Lobov 
and co-workers showed that the temporary hyaloid vessels can 
develop normally but fail to undergo regression in PU.1–/– mice, 
which lack macrophages (Lobov et al., 2005). In the developing 
mouse retina, macrophages are the main source of WNT7B, a 
molecule that induces cell-cycle progression and can predispose 
target cells to subsequent apoptosis (Lobov et al., 2005). Rao and 
co-workers further showed that macrophage-mediated vascular 
regression involves two distinct signals, WNT7B and ANG2 (Rao 
et al., 2007). ANG2 has long been regarded as a natural antagonist 
for ANG1 (Augustin et al., 2009), although recent studies have indi-
cated that it may also function as a context-dependent TIE2 agonist 
(Daly et al., 2006; Coffelt et al., 2010b). In the presence of ANG2 
produced by the hyaloid blood vessels, resident macrophages up-
regulate WNT7B, which induces the proliferation of vascular ECs 
and sensitizes them to ANG2-induced apoptosis. In the absence 
of ANG2, ANG1 signaling prevails and EC death is suppressed 
(Rao et al., 2007). Together, these data suggest that macrophages 
directly regulate retinal vascular remodeling, but not initiation of 
retinal angiogenesis. Because a sizable fraction of the embryonic 
macrophages express the TIE2 receptor or a Tie2-GFP reporter 
gene in transgenic mice (Fantin et al., 2010; Pucci et al., 2009; 
Gordon et al., 2010), it can be envisioned that ANG2 directly acts 
on macrophages via TIE2 to regulate WNT7B secretion (Rao et 
al., 2007). It should be noted, however, that one study suggested 
that cytotoxic T cells – rather than macrophages – promote vas-
cular regression and remodeling of the primary retinal plexus by 
inducing Fas ligand-mediated EC apoptosis (Ishida et al., 2003).
During pregnancy, angiogenesis and vascular remodeling at the 
maternal-fetal interface ensure continuous blood flow to the fetus. 
Inadequate angiogenesis and vascular remodeling limit extraem-
bryonic trophoblast invasion of the decidua (the maternal uterine 
mucosa during pregnancy) and may cause pre-eclampsia and 
miscarriage (Harris, 2010). Both in mice and humans, macropha-
ges and natural killer (NK) cells infiltrate the human decidua and 
regulate spiral artery remodeling at the maternal-fetal interface. 
Decidual NK cells, but not peripheral blood-derived NK cell subsets, 
were shown to promote trophoblast invasion and angiogenesis by 
secreting interleukin-8 (IL-8) and many other proangiogenic factors 
(Hanna et al., 2006). Interestingly, both macrophages and NK cells 
are absent from intact arteries, but accumulate in significant num-
bers in and around remodeling arteries (Harris, 2010). According 
to Hazan and co-workers, spiral artery remodeling may depend on 
matrix-metalloproteinase (MMP)-9, which is essentially produced 
by the macrophages and NK cells in the decidua (Hazan et al., 
2010). These MMP9-expressing leukocytes were shown to be in 
close association with blood vessels during the early phases of 
remodeling, and MMP2/9 inhibition in human placental-decidual 
explants resulted in failure of vascular remodeling (Hazan et al., 
2010). These data therefore suggest that macrophage-derived 
MMPs facilitate cell migration, invasion and vascular remodeling 
during pregnancy.
In summary, there is now compelling evidence for macrophages 
to regulate vascular morphogenesis during development and post-
natal tissue/organ remodeling. In addition to expressing classic 
proangiogenic and tissue-remodeling factors, which may initiate 
angiogenesis, macrophages appear to support the formation of 
a functional vascular system by (i) assisting directional vessel 
growth via cell-to-cell contacts and/or their production of guidance 
factors that act iuxtacrinally on vascular sprouts after the induction 
of EC proliferation and angiogenesis; (ii) pruning primitive blood 
vessels (via secretion of proapoptotic factors) to remodel the 
vascular network. 
Macrophage regulation of angiogenesis in tissue injury 
and repair
Macrophages likely represent the preeminent cells in the body 
endowed with the ability to migrate within tissues – even in hypoxic 
conditions – and with the capacity to modify the ECM and amplify 
paracrine signals. For example, in a transgenic model of ischemic 
cardiomyopathy in which monocytes are attracted to the myocar-
dium by the targeted overexpression of CCL2 (a CC-chemokine 
formerly known as monocyte chemoattractant protein-1, MCP-1), 
monocytes/macrophages were found to drill tunnels in the ECM 
to facilitate the subsequent in-growth of new capillaries (Moldovan 
et al., 2000). Macrophages may thus provide temporary scaffolds 
or paracrine support for the expansion and maturation of vascular 
networks, both in development (see above) and in pathophysio-
logical conditions. 
Wound healing is a complex biological process that occurs fre-
quently during adulthood and requires the interplay among different 
cell types, including keratinocytes, fibroblasts and immune cells 
(Martin, 1997; Rodero et al., 2011). Early studies suggested that 
macrophages and neutrophils play a crucial role during skin wound 
healing (Leibovich and Ross, 1975). Macrophages are generally be-
lieved to orchestrate the repair process by acting both as phagocytes 
(to clear cellular debris) and as a major source of growth factors 
(e.g., proangiogenic factors; epithelial-cell growth factors; etc…). 
Martin and co-workers however showed that macrophage-deficient 
PU.1–/– mice are able to repair skin wounds with similar time course 
to wild-type siblings (Martin et al., 2003). Yet, healed skin wounds 
in macrophage-deficient mice showed minimal scar formation, a 
likely consequence of the reduced inflammatory response and 
lower rate of keratinocyte cell death occurring in the absence of 
proinflammatory macrophages (Martin et al., 2003). More recent 
studies however showed that macrophages recruited during the 
diverse phases of skin repair (i.e., the inflammatory; tissue forma-
tion; and tissue maturation phases) exert distinct functions (Lucas 
et al., 2010). By crossing transgenic mice that express the CRE 
recombinase from the lysozyme M (LysM) promoter, with transgenic 
mice that express the human diphtheria toxin (DT) receptor upon 
CRE-mediated recombination, the authors generated mice in which 
depletion of macrophages and other myeloid cells can be induced 
during specific stages of the repair response. Depletion of myeloid 
cells during the early stages of the repair response (inflammatory 
phase) significantly reduced the formation of vascularized granu-
lation tissue, impaired epithelialization, and resulted in minimized 
scar formation (Lucas et al., 2010), the latter finding in agreement 
with the study of Martin and co-workers (Martin et al., 2003). In 
contrast, depletion of macrophages during the subsequent phase of 
the repair response (tissue formation) caused severe hemorrhage 
in the wound tissue and prevented tissue maturation and wound 
closure. Finally, macrophage depletion during the late stage of repair 
(tissue maturation) did not significantly impact the outcome of the 
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repair response (Lucas et al., 2010). These interesting observations 
suggest that macrophages exert distinct functions during the diverse 
phases of skin repair. In particular, macrophages appear to play 
an important role in promoting (i) angiogenesis in the granulation 
tissue during the early phase of skin repair; (ii) vascular maturation 
and stabilization in the subsequent phases (Lucas et al., 2010).
Tissue macrophages can display different activation states 
according to the stimuli present in the local microenvironment. In 
several microbial infections and other inflammatory conditions, the 
products of activated T helper-1 (Th1) lymphocytes and NK cells 
(e.g., interferon-gamma, IFNg) can induce macrophages to under-
go a “classical activation” (or “M1”) program that enhances their 
cytotoxic and antimicrobial activity. Conversely, signals produced 
by Th2 polarized lymphocytes (e.g., IL4, IL10 or IL13) can induce 
macrophages to acquire an “alternative activation” (or “M2”) status 
in various pathophysiological conditions, such as wound healing 
and granuloma formation, or in certain disease conditions, such 
as fibrosis, atherosclerosis, stroke, and cancer (Gordon, 2003; 
Gordon and Martinez, 2010; Mantovani et al., 2002).
Distinct “types” of wound healing macrophages have been 
described to date; their phenotypic and functional characterization 
is, however, not yet exhaustive (Rodero et al., 2011). Okuno and 
co-workers recently showed that the majority of BM-derived cells 
infiltrating both acute (dorsal excisional ear punch) and chronic (de-
cubitus ulcer) skin wounds are macrophages (Okuno et al., 2011). 
Most of these macrophages display an “alternatively” activated or 
M2-like phenotype (Gordon, 2003; Gordon and Martinez, 2010), 
e.g., express high levels of MRC1 and low levels of nitric oxide 
synthase-2 (NOS2) and IL-6. Interestingly, the authors found that 
the majority of these macrophages were located in perivascular 
areas at the wound healing site (Okuno et al., 2011).
Recruitment of macrophages to the wound healing site may 
rely on different signals, such as CCL2/MCP1, macrophage in-
flammatory protein-1alpha (MIP1a), but also stromal cell-derived 
factor 1 (SDF1)/CXCL12 and G-CSF (Wu et al., 2010). Okuno and 
co-workers showed that CSF-1 is early up-regulated at the wound 
healing site and plays an important role in recruiting macrophages 
(Okuno et al., 2011). This was confirmed by inhibition of CSF-1R 
or CSF-1, which resulted in 80% reduction of the macrophage 
infiltrate. Moreover, the authors observed delayed wound healing 
in Csf-1op/op mice, and this correlated with decreased vascular 
density. However, the overall amounts of classic proangiogenic 
factors produced at the wounded site did not differ between Csf-1op/
op and wild-type mice, whereas MMPs were significantly reduced. 
Thus, wound healing macrophages may exert their proangiogenic 
programs by physically interacting with sprouting blood vessels, 
facilitating their growth by degrading the ECM, and/or promoting 
vascular remodeling via non-canonical (e.g., VEGF-independent) 
angiogenic pathways (Okuno et al., 2011).
Sindrilaru and co-workers recently reported that human chro-
nic venous ulcers contain increased proportions of macrophages 
expressing M1-type markers (e.g., NOS2 and tumor necrosis 
factor-alpha (TNFa)) than healing wounds (Sindrilaru et al., 2011). 
As mentioned above, “classically” activated or M1-polarized ma-
crophages sustain tissue inflammation and actively phagocytose 
dead cells, cellular debris and microbes (Gordon, 2003; Gordon 
and Martinez, 2010). The authors found that iron deposits and their 
subsequent uptake by macrophages in chronic wounds impaired 
macrophage switching from the M1-like to the M2-like phenotype, a 
phenotypic switch that instead occurs in healing wounds (Sindrilaru 
et al., 2011). Together with previous reports (Okuno et al., 2011; 
Rodero et al., 2011), this study suggests that M1-like macrophages 
prevail in early or chronic wounds, where they prevent infection 
and help clearance of necrotic tissue (Sindrilaru et al., 2011). 
Conversely, proficient wound healing requires the participation 
of M2-like macrophages, which may either originate from M1-like 
macrophages or from different monocyte precursors.
Macrophages have also been implicated in the healing/regene-
ration of the nervous tissue. Barrette and co-workers showed that 
the depletion of CD11b+ myeloid cells in CD11b-HSV-thymidine 
kinase transgenic mice impaired recovery of sciatic nerve function 
after injury (Barrette et al., 2008). Depletion of myeloid cells was 
associated with a significant decrease in vascular density and 
delayed neural cell proliferation (Barrette et al., 2008). Kigerl and 
co-workers further observed that M2-like macrophages transiently 
increase at the spinal cord injury site (Kigerl et al., 2009). In this 
study, the authors also showed that neurons co-cultured with 
M2-like macrophages displayed more neuritis, and their axons 
projected over longer distances, compared to neurons co-cultured 
with M1-like macrophages (Kigerl et al., 2010). These interesting 
observations suggest that M2-like macrophages participate in 
both vascular network formation and neural development. In 
this regard, it is increasingly appreciated that blood vessels and 
neurons share cell-surface receptors and guidance cues, such as 
several members of the VEGF and Semaphorin/Plexin families, 
to control their behavior during embryogenesis and, possibly, also 
in selected pathophysiological conditions during post-natal life 
(Fantin et al., 2009).
The role of macrophages in lymphangiogenesis
Lymphatic vessels regulate tissue fluid homeostasis and play 
a crucial role in immune cell trafficking. The molecular pathways 
involved in lymphangiogenesis have been elucidated more in detail 
in the context of development. In the adult, lymphangiogenesis 
occurs in inflammation, tumors, and during the process of wound 
healing. In the mouse embryo, lymphangiogenesis begins at 9.5-
10.5 dpc, after the cardiovascular system is formed (Tammela and 
Alitalo, 2010). Lymphatic ECs arise from specialized subpopulations 
of ECs in the anterior cardinal vein; these specialized ECs are 
positive for prospero-related homeodomain transcription factor 
(PROX-1), which is the master molecular switch for lymphatic EC 
determination, and hyaluronan receptor-1 (LYVE1). 
In addition to angiogenesis, macrophages also appear to regulate 
lymphangiogenesis. For example, CSF-1 deficiency in Csf-1op/op 
mice reduces the abundance of macrophages in the developing 
trachea, resulting in defects in both vascular and lymphatic deve-
lopment (Kubota et al., 2009). Bohmer and co-workers recently 
described a population of monocyte-lineage cells, defined by the 
expression of Syk tyrosine kinase (Bohmer et al., 2010). These 
cells were characterized by their robust expression of proangiogenic 
factors, such as fibroblast growth factor-2 (FGF2), platelet-derived 
growth factor-B (PDGF-B), MMP2 and MMP9, as well as lymphan-
giogenic growth factors (VEGF-C and VEGF-D). Interestingly, the 
skin of Syk-decifient embryos showed increased accumulation of 
these proangiogenic monocyte-lineage cells, which expressed 
a more pronounced proangiogenic profile than their wild-type 
counterpart (Bohmer et al., 2010). The enhanced infiltration by 
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lymphangiogenic monocytes in Syk-deficient embryos caused 
lymphatic hyperplasia, vessel dilation leading to blood-lymphatic 
shunts, and lethality during mid-gestation. Interestingly, the Syk-
expressing monocytes also express TIE2 (Bohmer et al., 2010) 
and display many similarities with the TIE2-expressing monocytes/
macrophages found in tumors and embryos (Pucci et al., 2009). 
Another recent study showed that clodronate-liposome–mediated 
depletion of VEGF-C–expressing, dermal macrophages counteracts 
hyperplasia of lymphatic capillaries in response to high-salt diet 
(Machnik et al., 2009). Taken together, these findings (Bohmer et 
al., 2010; Machnik et al., 2009) indicate that, in addition to angio-
genesis, monocyte/macrophages may also regulate lymphangio-
genesis. Furthermore, they suggest that the enhanced recruitment 
of monocyte/macrophages that occurs in certain pathological 
conditions (e.g., salt-sensitive hypertension) may induce lymphatic 
hyperplasia and pathological lymphangiogenesis.
Another recent report implicated macrophages in lymphangio-
genesis (Gordon et al., 2010). In this study, the authors showed 
that 14.5-18.5 dpc PU.1–/– and Csf-1r–/– mice display hyperplastic 
lymphatic vessels in the skin. This phenotype appears to be due to 
the specific lack of myeloid-lineage cells, since lymphocyte-deficient 
Rag2–/– mice did not show hyperplastic lymphatic vessels in the 
skin (Gordon et al., 2010). Although skin macrophages appeared 
dispensable for lymphatic vessel sprouting and branching, they 
influenced lymphatic vessel caliber, possibly by controlling either the 
proliferation or apoptosis of lymphatic ECs in the developing skin. 
In apparent contradiction with other studies (Bohmer et al., 2010), 
the findings of Gordon and co-workers (Gordon et al., 2010) also 
imply that macrophages may not comprise the principal source of 
pro-lymphangiogenic growth factors (including VEGF-C and VEGF-
D) in the embryonic dermal microenvironment, and also suggest 
that the sources of proliferative and patterning signals driving em-
bryonic lymphangiogenesis are likely to be distinct (Gordon et al., 
2010). The authors further characterized the dermal macrophages 
and identified a subset of LYVE1+ cells that intimately associated 
with the developing lymphatic vasculature. Interestingly, the gene 
expression profile of these LYVE1+ macrophages overlaps with that 
of both embryonic and tumor-derived TEMs (Pucci et al., 2009). 
Because these LYVE1+ macrophages provide only 10% of the pro-
lymphangiogenic molecules present in the dermal microenvironment 
(Gordon et al., 2010), it is tempting to speculate that, in analogy 
with developmental (Fantin et al., 2010) and tumor (Mazzieri et 
al., 2011) angiogenesis, TEM-like embryonic macrophages are not 
essential for lymphatic vessel sprouting but play an important role in 
lymphatic vessel expansion and remodeling (Gordon et al., 2010). 
Similarities between embryonic and tumor-associated 
macrophages (TAMs)
In order to grow over a few millimeters in size, incipient tumors 
need to generate their own vasculature to enable oxygen and 
nourishment delivery to the expanding tumor cells (Carmeliet, 
2005). It is now well established that tumor-associated stromal 
cells such as macrophages (TAMs), neutrophils and fibroblasts 
cooperate with tumor cells to facilitate angiogenesis in tumors 
(Squadrito and De Palma, 2011; Coffelt et al., 2010a; Egeblad et 
al., 2010; Murdoch et al., 2008).
In several mouse tumor models, macrophages represent the 
most abundant tumor-infiltrating myeloid cells (Squadrito and De 
Palma, 2011). The early finding that high macrophage counts co-
rrelate with higher tumor angiogenesis in some human tumor types 
(Leek et al., 1996) suggested that these cells might exert a direct 
proangiogenic function in tumors. However, compelling evidence 
for the ability of macrophages to promote tumor angiogenesis was 
only provided using mouse models of in vivo monocyte/macrophage 
deficiency or adoptive transfer. De Palma and co-workers showed 
that the genetic depletion of TEMs was sufficient to robustly inhibit 
angiogenesis in various subcutaneous tumor models (De Palma et 
al., 2003; De Palma et al., 2005). Moreover, by crossing Csf1op/
op mice with mice that develop oncogene-induced mammary 
Fig. 1. Presence of Tie2-GFP+ macrophages in the mouse embryo. (A) Several Tie2-GFP+CD45+ Tie2-expressing macrophages (TEMs; white arrows 
and inset on top right) are present in the developing brain of a Tie2-GFP transgenic embryo. Note that in Tie2-GFP transgenic mice, both vascular 
endothelial cells and TEMs express GFP from the Tie2 promoter/enhancer. TEMs are labeled in green (GFP); hematopoietic cells in red (CD45); blood 
vessels in blue (CD31). (B) Tie2-GFP+F4/80+MRC1+ TEMs (arrowheads) are present in the developing eye of a Tie2-GFP transgenic embryo. Note the 
proximity of GFP+ TEMs to the GFP+ hyaloids blood vessels. TEMs are labeled in green (GFP); macrophages in red (MRC1) and blue (F4/80). Sections 
were obtained from late-stage embryos.
BA
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tumors (MMTV-PyMT), Lin and co-workers found that the tumors 
of these macrophage-deficient mice had reduced angiogenesis 
and delayed progression to malignancy (Lin et al., 2006). Finally, 
the depletion of tissue macrophages by clodronate-liposomes 
resulted in delayed angiogenesis and tumor growth in various 
tumor models (Zeisberger et al., 2006). Together, these studies 
have highlighted the important role played by macrophages in 
tumor angiogenesis. Several mechanisms may be involved, such 
as macrophage production of a plethora of proangiogenic growth 
factors and chemokines. Moreover, TAMs can mobilize angiogenic 
growth factors embedded in the ECM thanks to their secretion of 
many proteases and other matrix-remodeling enzymes (Murdoch et 
al., 2008). As mentioned above, similar to embryonic macrophages 
(Fantin et al., 2010), subsets of TAMs – such as TEMs – can also 
interact directly with tumor ECs to facilitate blood vessel growth 
(De Palma et al., 2005; Mazzieri et al., 2011).
Ojalvo and co-workers performed gene expression analyses of 
TAMs isolated from late-stage, MMTV-PyMT mammary tumors, 
and compared their gene expression signature with that of sple-
nic and embryonic macrophages (Ojalvo et al., 2009). The data 
highlighted the tissue trophic functions of TAMs and their similarity 
with embryonic but not splenic macrophages. Pucci and co-workers 
further showed that TIE2+ embryonic/fetal macrophages, which 
appear at 8.5 dpc, show common features with tumor-infiltrating 
TEMs (Pucci et al., 2009). In the embryo, TEMs are particularly 
enriched in the mesenchyme surrounding neural organs; these 
TIE2+ macrophages are often found in close proximity to blood 
vessels at distinct anatomical sites, including the hyaloid cavity of 
the eye (Fig. 1). Gene expression analyses further indicated that 
embryonic/fetal TEMs are molecularly similar to tumor-associated 
TEMs (Pucci et al., 2009). Indeed, embryonic TEMs express the 
typical tumor TEM markers MRC1, haptoglobin/hemoglobin sca-
venger receptor (CD163), neuropilin-1 (NP1), stabilin-1 (STAB1), 
and LYVE1. Interestingly, tumor TEMs express lower VEGF levels 
that classic, TIE2-negative (inflammatory) TAMs (Pucci et al., 2009). 
This may be consistent with the observation that TEMs preferen-
tially reside around newly formed tumor blood vessels in viable 
tumor areas (note that VEGF is strongly upregulated in cells that 
reside in hypoxic or necrotic microenvironments). The finding of 
lower VEGF expression in TEMs than classic TAMs also suggests 
that the former are likely to promote tumor angiogenesis mostly 
in a VEGF-independent manner. Our recent studies suggest that 
tumor TEMs, similar to TIE2+ embryonic macrophages (Fantin et 
al., 2010), promote the formation of a functional tumor-associated 
vasculature by associating with sprouting tumor blood vessels, and 
that this function is regulated by the ANG2/TIE2 axis in macropha-
ges (Mazzieri et al., 2011).
It should be emphasized that embryonic and tumor macrophages 
have different origins: whereas fetal macrophages are derived from 
the extra-embryonic mesoderm (yolk sac), tumor macrophages likely 
originate from HSC-derived monocytes (De Palma et al., 2003). 
Thus, it can be speculated that embryonic macrophages and spe-
cific TAM subsets, such as TEMs, express similar gene signatures 
as a result of convergent functional adaptation. Whereas TEMs 
generally constitute a minor macrophage subset in mouse tumors 
(Squadrito and De Palma, 2011), the majority of macrophages 
seem to express a TEM-like phenotype in the developing embryo 
(Fantin et al., 2010; Pucci et al., 2009). This may reflect the fact 
that variably inflamed, hypoxic, necrotic, hemorrhagic, as well as 
avascular or highly vascularized microenvironments are present 
in any given tumor. Such degree of histological heterogeneity is 
accompanied by a remarkable heterogeneity of macrophage phe-
notypes (Lewis and Pollard, 2006; Mantovani et al., 2008; Qian 
and Pollard, 2010; Squadrito and De Palma, 2011). It appears that 
tumor TEMs mostly reside in viable and angiogenic tumor areas, 
whereas they are mostly excluded from necrotic, inner tumor areas 
(De Palma and Naldini, 2009). Developing embryos do not contain 
inflamed, necrotic or hemorrhagic microenvironments, but require 
sustained angiogenesis and tissue remodeling to support organ 
growth. These microenvironmental features may skew macrophage 
recruitment/differentiation toward a TEM-like (proangiogenic and 
pro-remodeling) phenotype, and even prevent the generation of 
cytotoxic (or proinflammatory) macrophages.
A recent study reported the generation of TEM-like, proan-
giogenic monocytes/macrophages from human embryonic stem 
cells (ESCs) (Klimchenko et al., 2011). These TIE2+ ESC-derived 
monocytic cells displayed enhanced expression of genes encoding 
matrix-degrading enzymes, proangiogenic factors and scavenger 
receptors, as was previously reported for tumor TEMs and other 
M2-like macrophages (Pucci et al., 2009). Furthermore, they pro-
moted vascular remodeling in xenotransplanted human tumors 
(Klimchenko et al., 2011). The generation of TEM-like cells from 
ESCs may offer a valuable experimental tool for in vitro studies 
and, possibly, provide a source of proangiogenic cells for the 
treatment of ischemia, injured tissues and chronic wounds. Finally, 
it is conceivable that better characterizing the developmental roles 
of macrophages – including their genetic programs facilitating an-
giogenesis and tissue morphogenesis in developing organs – may 
provide clues to TAM function in cancer and identify molecular 
targets that could be exploited to inhibit their proangiogenic and 
protumoral activities in human neoplasia and in other diseases.
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